Core Viewpoint - Ally Bridge Group NY LLC significantly reduced its stake in LENZ Therapeutics by 48.9% during the third quarter, indicating a potential shift in investment strategy or confidence in the company [2] Institutional Investment Activity - Versant Venture Management LLC acquired a new stake in LENZ Therapeutics valued at approximately $123.76 million during the third quarter [3] - Adage Capital Partners GP L.L.C. increased its stake by 108.8% in the second quarter, now holding 1,122,738 shares worth $32.91 million after acquiring an additional 585,000 shares [3] - Franklin Resources Inc. raised its position by 6,756.1% in the third quarter, owning 587,084 shares valued at $27.35 million after acquiring 578,521 shares [3] - UBS Group AG increased its stake by 36.3% in the third quarter, now owning 1,201,616 shares valued at $55.97 million after acquiring 320,135 shares [3] - Hedge funds and institutional investors collectively own 54.32% of LENZ Therapeutics [3] Analyst Ratings - HC Wainwright maintained a "buy" rating for LENZ Therapeutics [4] - Wall Street Zen upgraded the stock from "sell" to "hold" [4] - Zacks Research downgraded the stock from "strong-buy" to "hold" [4] - Weiss Ratings reiterated a "sell (d-)" rating [4] - William Blair reissued an "outperform" rating [4] - The consensus rating for LENZ Therapeutics is "Moderate Buy" with a price target of $56.40 [4] Stock Performance - LENZ Therapeutics opened at $12.15, with a market cap of $380.17 million [5] - The stock has a 50-day simple moving average of $15.01 and a 200-day simple moving average of $25.99 [5] - The one-year low for the stock is $11.21, while the one-year high is $50.40 [5] - The company has a P/E ratio of -5.76 and a beta of 0.52 [5] Company Overview - LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies to improve vision in the U.S. [6] - Its product candidates, LNZ100 and LNZ101, are in Phase III clinical trials for treating presbyopia [6]

As filed with the Securities and Exchange Commission on September 11, 2024 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 LENZ THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 84-4867570 (I.R.S. Employer Identification Number) 201 Lomas Santa Fe ...

As filed with the Securities and Exchange Commission on April 8, 2024 Registration No. 333-278393 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 LENZ THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 84-4867570 (I.R.S. Employer Identification Nu ...

As filed with the Securities and Exchange Commission on April 8, 2024 Registration No. 333-278393 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 84-4867570 (I.R.S. Employer Identification Number) 445 Marine View Ave., Ste. #320 Del Mar, California 92014 (858) 925-7000 (Address, including zip code, and ...

As filed with the Securities and Exchange Commission on March 29, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 LENZ THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 84-4867570 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 445 Marine View Ave., Ste. #320 Del Mar, ...

As filed with the Securities and Exchange Commission on March 29, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 LENZ THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 84-4867570 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (Address, including zip code, and telephone number, including area code, of Regi ...